左心室辅助装置受者的器械治疗与心律失常管理:美国心脏协会科学声明
该科学声明由电生理学家、心衰专科医生、心脏外科医生和心血管专科护士组成的小组基于全面文献综述制定,旨在回顾现有证据并为左心室辅助装置(LVAD)受者的房性与室性心律失常管理、程序性干预及心血管植入式电子设备(CIED)和心脏再同步治疗(CRT)的程控策略提供指导。声明简要回顾了商用LVAD的结构与设计及植入指征,并重点阐述了长期连续流循环支持的生理效应以及LVAD支持下心律失常的机制与临床意义。
要点
- LVAD受者房性与室性心律失常常见,增加风险并复杂化患者管理。
- 尽管多数患者已有CIED或CRT,LVAD植入后常维持CIED检测与治疗。
- 现有数据对LVAD植入后CIED疗效及最佳程控策略存在矛盾。
核心结论
- 本科学声明基于全面文献综述,为LVAD受者房性与室性心律失常的管理、程序性干预及CIED/CRT程控策略提供指导。
研究设计与样本
- 由电生理学家、心衰专科医生、心脏外科医生和心血管专科护士组成的专家组基于全面文献综述制定。
主要发现
- LVAD受者房性与室性心律失常常见,易导致额外风险并复杂化患者管理。
- 多数LVAD患者已有CIED或CRT,且心衰自然病程下常维持CIED检测与治疗。
- 现有数据对LVAD植入后CIED疗效及最佳程控策略存在矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure with reduced ejection fraction. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common, predispose these patients to additional risk, and complicate patient management. However, there is no consensus on best practices for the medical management of these arrhythmias or on the optimal timing for procedural interventions in patients with refractory arrhythmias. Although the vast majority of these patients have preexisting cardiovascular implantable electronic devices or cardiac resynchronization therapy, given the natural history of heart failure, it is common practice to maintain cardiovascular implantable electronic device detection and therapies after LVAD implantation. Available data, however, are conflicting on the efficacy of and optimal device programming after LVAD implantation. Therefore, the primary objective of this scientific statement is to review the available evidence and to provide guidance on the management of atrial and ventricular arrhythmias in this unique patient population, as well as procedural interventions and cardiovascular implantable electronic device and cardiac resynchronization therapy programming strategies, on the basis of a comprehensive literature review by electrophysiologists, heart failure cardiologists, cardiac surgeons, and cardiovascular nurse specialists with expertise in managing these patients. The structure and design of commercially available LVADs are briefly reviewed, as well as clinical indications for device implantation. The relevant physiological effects of long-term exposure to continuous-flow circulatory support are highlighted, as well as the mechanisms and clinical significance of arrhythmias in the setting of LVAD support.
引用
- Gopinathannair R, Cornwell WK, Dukes JW, et al. Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement From the American Heart Association. Circulation. 2019. PMID: 30943783. doi:10.1161/CIR.0000000000000673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。